Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Sanofi

New therapy teplizumab could delay type 1 diabetes by years – if caught early

For more than a century, type 1 diabetes has meant one thing: a lifetime administering insulin. But for the first time, science is breaking that paradigm – not by managing the disease, but by intercepting it before symptoms even appear.

The Conversation

French drug giant Sanofi plans massive US investment to counter Trump tariffs

French pharmaceutical giant Sanofi plans to invest billions of euros to expand its manufacturing in the United States, in response to President Donald Trump’s trade policies – which include threats to impose tariffs on medicines in order to increase homegrown production.

Radio France Internationale

Chrissy Teigen is sharing what it was like to see her son Miles, 6 diagnosed with Type 1 diabetes: 'It was just so shocking'

“All of a sudden we were just thrown into having to learn everything imaginable the same day that he needed to start shots,” Teigen recounts.

Fortune

From analysis to the latest developments in health,
read the most diverse news in one place.

Acne vaccine: Experimental shot for common skin condition reaches clinical trials. Here's what you need to know.

An experimental vaccine for acne could someday transform the way patients with the condition are treated, according to the company that developed the shot. However, it is still early days.

LiveScience

Europe’s pharma titans confront von der Leyen as Trump plans ’major’ tariffs

Novo Nordisk and Sanofi were among the companies threatening to hasten their exits to the U.S., as Trump promised pharma tariffs were coming “shortly.”

Fortune

How Diabetes Patients Are Fighting for Affordable Insulin

The World Health Organization states that there were around 830 million people living with diabetes in 2022. More than half of them weren't taking diabetes medications, including insulin, likely due to access and cost issues.

inkl

Sanofi exec says remote work takes away employee 'serendipity'

"I think we were contrarians,” Sanofi's chief digital officer Emmanuel Frenehard told Fortune. “I think the contrarians are becoming the norm.”

Fortune

Read news from The Economist, FT, and more,
with one subscription

Regeneron: Is It the Perfect Biotech Stock for Value and Growth?

Regeneron is trading at historically low valuations as its Dupixent blockbuster drug could get a 30% increase in TAM if the FDA approves its use in COPD.

MarketBeat

3 Gene Therapy Stocks With Game-Changing Potential

Gene therapy stocks are transforming healthcare with revolutionary treatments. Therefore, as this sector continues to evolve, investing in gene therapy stocks like Pfizer (PFE), Sanofi (SNY), and Novartis AG (NVS) could be beneficial. Read on….

StockNews.com

Why Olympian Jordan Chiles is raising awareness of type 1 diabetes

“If I had type 1 diabetes as an athlete, I don't think I could be as strong as how my aunt is right now," Chiles says about her inspiration for advocacy work.

Fortune

3 Pharma Stocks to Buy as California Sounds the Alarm on Bird Flu Cases

The bird flu crisis is creating investment opportunities in the pharmaceutical sector, with Sanofi, GSK, and CSL Limited emerging as top picks.

Barchart

Sanofi exec says remote work takes away employee 'serendipity'

“I think we were contrarians,” Sanofi’s chief digital officer, Emmanuel Frenehard, told Fortune. “I think the contrarians are becoming the norm.”

Fortune

Sanofi CEO Paul Hudson takes inspiration from 'Fight Club' to get his team hooked on AI

Hudson says many CEOs are scared of AI, comparing it to The Terminator’s John Connor traveling back in time to stop the rise of the machines.

Fortune

Epilepsy medication affected Sophie’s pregnancies. Should Australia adopt tougher guidelines?

Exclusive: FoI documents show Advisory Committee on Medicines considered tightening prescribing requirements for sodium valproate – but chose not to

The Guardian - AU

Get all your
news in one place.

100’s of premium titles.
One news app.

Fortune

Here’s what the top business leaders are saying about AI: 'You need to be prepared for anything'

CEOs at Fortune Global Forum unpack how AI will impact the labor market and corporate America.

Fortune

CEO of pharma giant Sanofi says businesses should stop 'AI washing'

Some companies are overselling AI without thinking through the risks, according to Paul Hudson

The Conversation

Bird flu has been detected in a pig in the US. Why does that matter?

The United States Department of Agriculture last week reported that a pig on a backyard farm in Oregon was infected with bird flu.

Radio France Internationale

Sanofi confirms €16 billion sale of painkiller Doliprane to US investors

French pharamceutical giant Sanofi has confirmed plans to sell a controlling stake in its over-the-counter unit to a US investment fund, after employment and investment guarantees relieved political controversy.

Get all your
news in one place.

100’s of premium titles.
One news app.

International Business Times

France Bristles At Painkiller Maker's Sale To US Fund

French drugmaker Sanofi's Monday confirmation that it plans to sell a controlling stake in its over-the-counter unit to a US investment fund sparked a new political backlash, stoked by fears the deal marks a loss of sovereignty over key medications.

The Guardian - UK

France warns US buyer of Sanofi division of penalties for shifting production abroad

Private equity firm CD&R revealed to be in exclusive talks to buy 50% stake in consumer healthcare arm Opella

International Business Times

Sanofi Pursues Sale Of Painkiller After Political Controversy

Sanofi confirmed on Monday plans to sell a controlling stake in its over-the-counter unit to a US investment fund, after employment and investment guarantees relieved political controversy.

The Guardian - UK

‘The UK is at the back of the race of turtles’: Sanofi’s boss on the need to develop new medicines

Paul Hudson, the Briton in charge of the French drug firm, is a big believer in the potential of AI to transform healthcare

Radio France Internationale

France could block sale of 'best-selling' drug if production doesn't stay local

France’s Economy Minister has warned that the government could block the sale of a subsidiary of the French pharmaceutical company Sanofi to a US private equity firm if it cannot guarantee that its production of paracetamol, under the name Doliprane, remains in France.

International Business Times

Painkiller Sale Plan To US Gives France Major Headache

The planned sale of France's best-selling medical drug to US investors has caused the government a splitting headache after an outcry against the project from politicians on all sides.

France 24

Pharmaceutical giant Sanofi looks to sell consumer health unit, sparks political uproar

France's Economy and Industry ministers, Antoine Armand and Marc Ferracci, are heading to Lisieux this Monday to visit the production sites of popular headache reliever Doliprane. The visit takes place after the maker of the pill, French pharma group Sanofi, said it was in talks to sell off its consumer…

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

International Monetary Fund

the World Health Organization

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.